# A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

> **NCT07733180** · PHASE2 · RECRUITING · sponsor: **BeOne Medicines** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Esophageal Squamous Cell Carcinoma
- Metastatic Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** 5-fluorouracil (5-FU)

## Key facts

- **NCT ID:** NCT07733180
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-14
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733180, "A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*